Infinant Health

Infinant Health

Biotechnology Research

Davis, California 5,103 followers

We're changing the trajectory of human health, one baby at a time. Intent on a world without debilitating disease.

About us

Infinant Health, Inc is a privately held company committed to changing the trajectory of human health, one baby at a time, through our deep understanding of infant nutrition and the gut microbiome. Years of proprietary research into the role of breast milk and its impact on human development led to our groundbreaking discovery of B. infantis EVC001, a natural bacterial strain foundational to infant immune health. Unfortunately, B. infantis had been almost completely eradicated from infants in developed countries due to unintended consequences of modern medicine such as feeding and birthing practices. Now, there is a way to change that. What we found is that EVC001, our specific strain of B. infantis, is essential in developing a healthy microbiome, and supporting healthy immune system function. We believe the greatest chance to impact future health begins early, right after birth—a once in a lifetime opportunity where rapid development and radical changes occur. By unlocking human nutrition's full potential through introducing beneficial bacteria during early infancy, we can help build a foundation for better health. Investors in Infinant Health include Cargill and Bill & Melinda Gates Foundation, among others.

Website
https://infinanthealth.com/
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Davis, California
Type
Privately Held
Founded
2012
Specialties
Infant Gut Microbiome, Pharmaceutical Development, Infant Health, Human Milk, Term/Preterm Infant Nutrition, Immune Development, Inflammation Control, Metagenomics, Machine Learning as a Medical Device (MLaMD), Software as a Medical Device (SaMD), Metabolomics, Drug Discovery, and Cognitive Development

Locations

Employees at Infinant Health

Updates

Similar pages

Browse jobs

Funding

Infinant Health 5 total rounds

Last Round

Series D

US$ 55.0M

See more info on crunchbase